全文获取类型
收费全文 | 855篇 |
免费 | 28篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 18篇 |
妇产科学 | 9篇 |
基础医学 | 227篇 |
口腔科学 | 13篇 |
临床医学 | 58篇 |
内科学 | 177篇 |
皮肤病学 | 19篇 |
神经病学 | 19篇 |
特种医学 | 12篇 |
外国民族医学 | 2篇 |
外科学 | 24篇 |
综合类 | 61篇 |
预防医学 | 31篇 |
眼科学 | 4篇 |
药学 | 89篇 |
中国医学 | 17篇 |
肿瘤学 | 128篇 |
出版年
2024年 | 1篇 |
2023年 | 11篇 |
2022年 | 8篇 |
2021年 | 18篇 |
2020年 | 13篇 |
2019年 | 18篇 |
2018年 | 13篇 |
2017年 | 13篇 |
2016年 | 12篇 |
2015年 | 16篇 |
2014年 | 19篇 |
2013年 | 62篇 |
2012年 | 26篇 |
2011年 | 47篇 |
2010年 | 28篇 |
2009年 | 34篇 |
2008年 | 36篇 |
2007年 | 48篇 |
2006年 | 34篇 |
2005年 | 30篇 |
2004年 | 44篇 |
2003年 | 33篇 |
2002年 | 21篇 |
2001年 | 31篇 |
2000年 | 33篇 |
1999年 | 35篇 |
1998年 | 28篇 |
1997年 | 35篇 |
1996年 | 32篇 |
1995年 | 33篇 |
1994年 | 26篇 |
1993年 | 17篇 |
1992年 | 14篇 |
1991年 | 19篇 |
1990年 | 11篇 |
1989年 | 7篇 |
1988年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
排序方式: 共有909条查询结果,搜索用时 15 毫秒
1.
目的:制备高表达GM-CSF的淋巴瘤细胞系,观察淋巴瘤细胞转染GM-CSF基因后生物学特性的改变。方法:将小鼠GF-CSF真核表达质粒用电穿孔法导入小鼠淋巴瘤细胞系RMA,有限稀释法制备单个细胞克隆,经RT-PCR,骨髓祖细胞增殖实验和集落形成实验筛选相对高表达GM-CSF的RMA克隆,并观察其生物学特性的改变。结果:获得了高表达GM-CS的RMA细胞系,其同基因动物体内致瘤性降低。结论:淋巴瘤细胞系RMA转染GM-CSF基因后致瘤性降低。 相似文献
2.
Hypereosinophilic syndrome in Hodgkin's disease with increased granulocyte-macrophage colony-stimulating factor 总被引:2,自引:0,他引:2
We report a patient with eosinophilia accompanied by Hodgkin's disease who showed remarkable increase in granulocyte-macrophage colony-stimulating factor (GM-CSF) in plasma but no increase in interleukin-5 (IL-5). The plasma GM-CSF level normalized as eosinophilia and lymphadenopathy disappeared after chemotherapy. Immunohistochemical study with immunoperoxidase staining technique showed a positive stain in lymph node cells by monoclonal anti-GM-CSF antibody. Eosinophilia is often accompanied by Hodgkin's disease, and several cases have been reported to show high levels of plasma IL-5. To our knowledge, this is the first report to show a high level of plasma GM-CSF in Hodgkin's disease with eosinophilia. 相似文献
3.
S Álvarez-Ruiz† PF Peñas† J Fernández-Herrera† J Sánchez-Pérez† J Fraga‡ A García-Díez† 《Journal of the European Academy of Dermatology and Venereology》2004,18(3):310-313
In the last years, granulocyte and granulocyte-macrophage colony-stimulating factors (G-CSF and GM-CSF) are being increasingly used and several cutaneous eruptions have been reported in relation to these treatments. In 1991 Horn et al. described three patients with maculopapular eruption that paralleled the time of infusion of GM-CSF. Two of the cases showed an increase in the number and size of macrophages in the biopsy specimen. Since then, several cases have been reported showing this histopathological alteration that has been considered characteristic of reaction to G-CSF or GM-CSF. Although maculopapular eruption with enlarged macrophages can appear after chemotherapy treatment, we have found that the presentation of this eruption after the beginning of cytokine treatment is suggestive of the involvement of G-CSF and GM-CSF in the eruption. We described eight cases of patients treated with G-CSF or GM-CSF that developed maculopapular eruptions with enlarged macrophages. 相似文献
4.
T Economopoulos E Papageorgiou N Stathakis N Asprou P Karmas J Dervenoulas H Bouronikou G Chalevelakis S Raptis 《European journal of haematology》1992,49(3):138-142
In a phase II study, 21 patients with MDS (RAEB, RAEBt, CMML and RA and RAS with severe cytopenia) were randomized to be treated with 3 courses of GM-CSF (3 micrograms/kg/day s.c.) alone (11 patients) or in combination with AraC (20 mg/m2/d s.c.) (10 patients) for 14-d periods, interrupted by 14-d rest periods. Eight patients discontinued the treatment. In the GM-CSF group a marked increase in WBC and neutrophil counts during each course of treatment administration were seen in most patients. Platelet counts decreased in 14 of 24 courses of treatment in the GM-CSF plus AraC group but in none of the GM-CSF group. Although the changes in the circulating blood cells were transient and the counts tended to return to the pretreatment levels during the rest periods, some more durable effects were seen. In 3/6 patients of the GM-CSF group who completed the designed treatment, both WBC and neutrophils remained elevated above the pretreatment levels throughout the 3-month period of treatment, while in one of them thrombocytopenia improved considerably. In the GM-CSF plus AraC group, 4 out of the 7 patients who completed the treatment showed an improvement of neutropenia as well as anaemia. In these 4 patients the BM percentage of blasts was also decreased. In conclusion, the results of this study indicate that GM-CSF given intermittently improves leukopenia in some patients with MDS. In addition, the administration of GM-CSF seems to prevent granulocytopenia of concurrent AraC treatment and may be of benefit in the treatment of these diseases. 相似文献
5.
W. R. Coward H. Sagara S. J. Wilson S. T. Holgate M. K. Church 《Clinical and experimental allergy》2004,34(7):1071-1078
BACKGROUND: Allergic inflammation is characterized by the influx and activation of eosinophils. Cytokines generated by both resident and infiltrating cells are responsible for the initiation and maintenance of this pathogenesis. This study focuses on allergen-induced activation of eosinophil NF-kappaB and generation of granulocyte macrophage-colony stimulating factor (GM-CSF), TNF-alpha, and IL-8. METHODS: Peripheral blood eosinophils were enriched to >99.9% by Percoll gradient sedimentation and negative magnetic affinity chromatography. NF-kappaB activation by 10 microg/mL house dust mite (HDM) extract was demonstrated immunocytochemically using a monoclonal antibody against the active form of NF-kappaB (NF-kappaBa). The authenticity of NF-kappaB was confirmed by Western blot. Cytokine production was assessed both by immuno-staining of eosinophils and by assay of cytokines in the cell supernatant. RESULTS: Activation of peripheral blood eosinophils from atopic, but not non-atopic, donors induced activation of NF-kappaB, which peaked at 4 h and was accompanied by a decline in IkappaB-alpha. The activation of authentic NF-kappaB was confirmed in gel shift assays. Supershift assays showed p65 to be the major subunit of eosinophil NF-kappaB. Immunofluorescent confocal microscopy demonstrated localization of NF-kappaBa to the nucleus. Following activation, cytokine immunoreactivity was seen in a fraction of the eosinophils and cytokines were released into the supernatant. The NF-kappaB inhibitors, calpain inhibitor 1 (10 microm), pentoxifylline (0.5 mm), pyrrolidine dithiocarbamate (PDTC, 10 microm) or gliotoxin (1 pg/mL) reduced the generation of GM-CSF, TNF-alpha and IL-8 in parallel with their inhibition of NF-kappaB. CONCLUSIONS: HDM allergen activates human eosinophil NF-kappaB leading to the production of the cytokines GM-CSF, TNF-alpha and IL-8. We speculate that a role for eosinophil NF-kappaB-dependent cytokines is to act as an autocrine loop augmenting the survival of eosinophils in vivo. 相似文献
6.
转FL、GM-CSF基因的人骨髓基质细胞促进脐血CD34+细胞体外扩增 总被引:1,自引:1,他引:1
研究转FL、GM-CSF基因的基质细胞对脐血CD34+细胞的扩增效应.将转FL、GM-CSF基因的入骨髓基质细胞系与脐血CD34+细胞共培养,观察细胞总数、CD34+细胞数、CFU-GM的变化情况.培养到第4周时,第(4)组(SCF+IL-3+IL-6+GM-CSF+FL)和第(8)组(HFCL/hGM-CSF+HFCL/hFL+SCF+IL-3+IL-6)的细胞总数增加到最大,分别扩增了717±24.47和709±63.63,第1周,第(5)组(HFCL+SCF+IL-3+IL-6)扩增了10.5±2.08倍,较第(8)组减少(P<0.05).第1周时,CD34+细胞总数第(4)组和第(8)组分别扩增了8.44倍和11.5倍(P<0.05),CD34+细胞百分率第(7)组(FCL/hFL+SCF+IL-3+II,-6)为50.2%,第(6)组(HFCL/hGM-CSF+SCF+IL-3+IL-6)为28.95%(P<0.01).第2周,各组CFU-GM增加显著,以第(4)组和第(8)组增加最为明显,以后随扩增时间延长,造血细胞集落数、集落体积逐渐减少.表明转FL、GM-CSF基因的基质细胞,能有效的协同其他细胞因子对脐血CD34+细胞产生明显的扩增作用,能显著改变基质细胞造血功能. 相似文献
7.
变应性鼻炎病人IL-4、IL-5和GM-CSF的水平观察 总被引:5,自引:1,他引:5
变态反应性鼻炎的发病机理与诸多细胞因子有关的现象,近年来已越来越受到国内外学者的重视[1]。变态反应性鼻炎发作时细胞因子的产生及炎性介质的参与均与机体异常的免疫调节有关,即存在T辅助细胞(TH)亚群功能失调,通过释放细胞因子,促进IgE的合成与分泌,并增加炎症细胞的浸润和活化。本文观察变应性鼻炎病人血清IL-4、IL-5和GM-CSF水平变化,为变应性鼻炎的防治提供依据。1材料与方法1. 1研究对象实验组为本院变态反应专科门诊确诊为尘螨变应性鼻炎(1997年修订,海口,变应性鼻炎诊断标准)病人86例,其中男性46例,女性40… 相似文献
8.
Marylne Fortin Marie-Jose Ouellette Raymond D. Lambert 《American journal of reproductive immunology (New York, N.Y. : 1989)》1997,38(2):129-139
PROBLEM: During normal pregnancy, major changes occur in the production of Th2/Th1 cytokines at the feto-maternal interface. Th2 cytokines such as interleukin-4 (IL-4) or interleukin-10 (IL-10) are predominantly produced locally in the uterine and placental tissues, whereas the production of Th1 cytokines such as tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) are decreased. Because these modulations might be induced by the embryo, the current study was carried out to test the effect of rabbit blastocoelic fluid on the production of Th2/Th1 cytokines by lymphocytes, and to investiate the possible implication of transforming growth factor β2 (TGF-β2) prostaglandin E2 (PGE2) as modulators of the production of these cytokines. METHOD OF STUDY: Human peripheral blood lymphocytes (PBL) were cultured along with ConcanavalinA (Con A), and rabbit blastocoelic fluid was collected on day 12 of gestation (BF d-12). Concentrations of cytokines in culture media were determined by enzyme-linked immunoadsorbent assay (ELISA). RESULTS: Addition of BF d-12 in the culture medium induced a strong inhibition of IL-2, TNF-α, IL-10, and granulocyte-macrophage colony-stimulating factor (GM-CSF) production. However, an initial pretreatment of the lymphocytes with BF d-12, followed by a Con A stimulation, led to a marked increase in GM-CSF production, whereas IL-2, TNF-α, and IL-10 secretions were inhibited. It was also demonstrated, for the first time, that a pretreatment of the lymphocytes with TGF-β2 and PGE2 increased GM-CSF production to the same level reached after the addition of BF d-12. Furthermore, removal of TGF-β2 and PGE2 from BF d-12 by affinity chromatography reduced the effect of BF d-12 on GM-CSF production. CONCLUSIONS: Taken together, these findings suggest that the embryo, in modulating harmful and beneficial cytokine production locally, plays an active role in its protection against maternal immune cellular assault. These results also emphasize the importance of growth factors for successfully maintaining pregnancy. 相似文献
9.
GM-CSF对MUC1基因疫苗抑制乳腺癌生长的增强作用 总被引:5,自引:2,他引:5
目的 :观察GM CSF有无增强MUC1基因疫苗对EMT6乳腺癌生长的特异性抑制作用。方法 :采用股四头肌肌肉注射法 ,将构建的MUC1基因疫苗pcDNA3.1 MUC1免疫雌性BALB/c小鼠 ,每 3wk 1次 ,共 3次。每次基因免疫后 1、3、5d ,皮下注射GM CSF 10 0 μL(1μg/ 10 0 μL)。最后 1次基因免疫后第 3周 ,接种表达MUC1的EMT6小鼠乳腺癌细胞。两周后观察、记录肿瘤的生长情况。于肿瘤细胞接种后第 4 3天 ,处死全部动物 ,称量肿瘤的质量。用 4h51Cr释放法检测小鼠脾特异性CTL的杀伤活性。结果 :接种肿瘤细胞后 4 3d ,MUC1基因疫苗加GM CSF组、MUC1基因疫苗组、pcDNA3.1加GM CSF组及pcDNA3.1组 ,EMT6肿瘤的大小依次为 (135± 33.8)mm3 、(2 5 0± 34.3)mm3 、(5 6 8± 4 3.6 )mm3 和 (5 96± 4 8.2 )mm3 ;平均瘤质量 (g)依次为 (0 .81± 0 .4 2 )g、(1.2 3± 0 .4 1)g、(2 .30± 0 .4 8)g及 (2 .2 8± 0 .5 8)g。与对照组相比较 ,MUC1基因疫苗组EMT6肿瘤的生长受到明显抑制 (P <0 .0 5 ) ;与单独MUC1基因疫苗组相比较 ,MUC1基因疫苗加GM CSF组抗肿瘤生长的作用有显著差异 (P <0 .0 5 )。在效靶比为 10 0∶1、5 0∶1、2 5∶1和 12 .5∶1时 ,MUC1基因疫苗加GM CSF组特异性CTL对EMT6靶细胞的杀伤率 ,依次为 6 8.5 %、 5 3.4 % 相似文献
10.
An interleukin-3-dependent progenitor clone LyD9 and its interleukin-4-dependent derivative clone K-4 were shown to differentiate into myeloid cells as well as B lymphocytes by coculture with bone marrow stroma cells. The K-4 clone is an intermediate between myeloid/lymphoid cells and the LyD9 clone that requires interleukin-4 for differentiation into B lymphocytes and myeloid cells. Granulocyte-macrophage colony stimulating factor-dependent derivatives (LS-1 and K-GM) were also established from induced LyD9 cells. LS-1 and K-GM were myeloid-committed cells. 相似文献